ResMed Inc. (NYSE:RMD) Director Peter C. Farrell sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $75.15, for a total value of $1,503,000.00. Following the sale, the director now directly owns 321,557 shares of the company’s stock, valued at approximately $24,165,008.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of ResMed Inc. (NYSE:RMD) traded up 0.38% during mid-day trading on Friday, reaching $73.07. The company had a trading volume of 529,536 shares. The company has a market capitalization of $10.39 billion, a price-to-earnings ratio of 30.45 and a beta of 0.83. The company has a 50 day moving average price of $75.87 and a 200 day moving average price of $72.42. ResMed Inc. has a one year low of $56.59 and a one year high of $79.63.

ResMed (NYSE:RMD) last released its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.02. The business had revenue of $556.69 million for the quarter, compared to analysts’ expectations of $557.68 million. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.74 EPS. On average, analysts anticipate that ResMed Inc. will post $3.03 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 21st. Stockholders of record on Thursday, August 17th will be issued a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a dividend yield of 1.92%. This is a boost from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date is Tuesday, August 15th. ResMed’s dividend payout ratio is presently 58.09%.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/19/peter-c-farrell-sells-20000-shares-of-resmed-inc-rmd-stock-updated.html.

Several research analysts have issued reports on the company. BMO Capital Markets increased their price target on ResMed from $61.00 to $70.00 and gave the stock a “market perform” rating in a report on Wednesday, August 2nd. Needham & Company LLC reiterated a “sell” rating on shares of ResMed in a report on Wednesday, August 2nd. Zacks Investment Research lowered ResMed from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Credit Suisse Group lowered ResMed from an “outperform” rating to a “neutral” rating in a report on Wednesday, August 2nd. Finally, Bank of America Corporation lowered ResMed from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Four analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. ResMed presently has an average rating of “Hold” and a consensus price target of $65.63.

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in ResMed by 5,439.8% in the first quarter. BlackRock Inc. now owns 13,335,138 shares of the medical equipment provider’s stock valued at $959,731,000 after buying an additional 13,094,421 shares during the last quarter. FMR LLC boosted its position in ResMed by 38.2% in the second quarter. FMR LLC now owns 5,542,582 shares of the medical equipment provider’s stock valued at $431,601,000 after buying an additional 1,531,772 shares during the last quarter. Koch Industries Inc. boosted its position in ResMed by 17,065.2% in the second quarter. Koch Industries Inc. now owns 985,796 shares of the medical equipment provider’s stock valued at $973,000 after buying an additional 980,053 shares during the last quarter. Morgan Stanley boosted its position in ResMed by 69.1% in the first quarter. Morgan Stanley now owns 1,344,234 shares of the medical equipment provider’s stock valued at $96,744,000 after buying an additional 549,279 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in ResMed by 4.6% in the first quarter. Vanguard Group Inc. now owns 11,535,707 shares of the medical equipment provider’s stock valued at $830,225,000 after buying an additional 508,392 shares during the last quarter. 60.66% of the stock is currently owned by hedge funds and other institutional investors.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Stock Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related stocks with our FREE daily email newsletter.